[ad_1]
According to Health Minister Arūnas Dulkys, the European Commission has asked Lithuania to decide on additional vaccines by Monday.
“We have to report if we would meet the relevant conditions: pro rata, we would have 5.58 million. doses of this vaccine, which would be available from 2022 and 2023, respectively. We suggest, given the delivery times that the vaccine has registered, that we have many people vaccinated with it who have good efficacy. And since we have to think about the need to ensure revaccination, please approve said purchase agreement, “said A. Dulkys at the Government meeting convened on Monday.
Prime Minister Ingrida Šimonytė asked if the EC had definitive answers on how many doses of vaccines would be needed to strengthen immunity. According to her, if one dose were enough to maintain immunity, this amount would be “more than enough” for a year. He proposed to support the position from now on that Lithuania would only participate in the procurement of basic quantities of vaccines for the time being, and that the purchase of additional quantities would depend on “additional information provided by science”.
“We have probably been able to ensure that the supply is sufficient and that the technology allows us to react in a somewhat more flexible way to the changes that are taking place with the virus in the world. But the main answer as to how much vaccine will be needed and how often is unlikely to be the one we have today, ”he said.
A. Dulkys assured that such solutions do not yet exist and that the issues will be discussed in the EC.
“Our total dose that we would have reserved from this company would be 9.2 million. vaccines. But here, only the position for the negotiations, as the principle itself says, would later show how the European Commission will succeed in the negotiations with Pfizer, he said.
According to data from the Ministry of Health, so far Lithuania has already approved almost 10.7 million. vaccines from eight manufacturers, most from Pfizer and BioNTech (3.7 million doses) and AstraZeneca (1.86 million doses).
[ad_2]
